Ozempic

Overview

Ozempic (semaglutide) is a once-weekly GLP-1 receptor agonist approved for type 2 diabetes, with indications to reduce cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to reduce kidney disease progression and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. While not FDA-approved for weight loss, widespread off-label prescribing has made it the most publicly recognized GLP-1 medication. The SUSTAIN trial program established its glycemic efficacy; the PIONEER program studied oral semaglutide (Rybelsus), and the STEP program studied the 2.4 mg Wegovy dose. Ozempic is now also sold as once-daily tablets (1.5, 4 and 9 mg), which are not scored here.

Mechanism of Action

Semaglutide activates the GLP-1 receptor, enhancing glucose-dependent insulin secretion, suppressing inappropriate glucagon release, slowing gastric emptying, and reducing appetite through centrally-mediated pathways. At the diabetes-indicated doses (0.5–2.0 mg), the primary therapeutic target is glycemic control with weight loss as a secondary benefit.

Clinical Evidence

The SUSTAIN trial program demonstrated superior HbA1c reduction versus comparators including sitagliptin, exenatide ER, and insulin glargine. SUSTAIN 6 showed 26% fewer major adverse cardiovascular events than placebo (hazard ratio 0.74), and FLOW showed a 24% lower risk of major kidney disease events (hazard ratio 0.76) in adults with type 2 diabetes and chronic kidney disease. At 2 mg, mean weight loss was 6.4 kg over 40 weeks in SUSTAIN FORTE. Weight loss in diabetes populations typically ranges from 4–6 kg at the 1 mg dose. When used off-label at higher doses or in non-diabetic populations, greater weight loss has been observed, though Wegovy (2.4 mg) is the approved weight-management formulation.

Side Effects & Safety

Nausea (15–20%), diarrhea, vomiting, constipation, and abdominal pain are the most common. GI side effects tend to be milder at diabetes-level doses (0.5–1.0 mg) compared to the weight-management dose (2.4 mg in Wegovy). Pancreatitis, gallbladder events, and diabetic retinopathy complications have been reported.

FAQ